John G. Devlin, M.D. | Hematology/Oncology


Board Certified in 2007

Board Certified in 2008

Internal Medicine
Board Certified in 2004


Bryn Mawr Medical Arts Pavilion
825 Old Lancaster Road
Suite 440
Bryn Mawr, PA 19010

Fax: (610) 525-8561

Education & Training

Medical School
Temple University School of Medicine

Temple University Hospital

Fox Chase Cancer Center
Temple University Hospital


Bryn Mawr Hospital – On staff since 2007

Lankenau Hospital – On staff since 2007

Paoli Hospital – On staff since 2007

Current Memberships & Activities

American Society of Clinical Oncology
American Society of Hematology
Sigma XI – National Research
PA Medical Society

Clinical/Dept. Titles

  • Principal Investigator for Main Line Health System, for Alliance Oncology Group, 2019-present
  • Vice-Chair, Main Line Health System Cancer Committee (INCP), 2015 – present
  • Member, Research Review Committee, MLHS, 2015 – present
  • Member, MLHS Center for Clinical Cancer Research, 2015 – present
  • Associate Principal Investigator, Main Line Health System CCOP/NCORP, 2013 – present
  • At-large Member, Medical Executive Committee, Main Line Health System, July 2013 – 2015
  • Campus Chief in Hematology/Oncology, Bryn Mawr Hospital, 2012 – present
  • At-large Member, Medical Operations Committee, Bryn Mawr Hospital, July 2011 – July 2013
  • Director, Clinical Laboratory, Bryn Mawr Medical Specialists Associates, March 2009 – 2012
  • Member, Institutional Review Board, Bryn Mawr Hospital, April 2009 – 2019
  • Ad-hoc Member, Ethics Committee, Bryn Mawr Hospital, January 2009 – present
  • Member, Cancer Committee, Bryn Mawr Hospital, Sept 2007 – present

Recent Clinical Studies Published

  • Simone C, Devlin JG, Singhal S, Langer CJ. Adenoid Cystic Carcinoma of the Lung. Textbook of Uncommon Cancer 5th edition. Raghavan D, Brecher ML, Johnson D, et al. (editors). John Wiley and Sons, 2017, pp.315-326.
  • Devlin JG, Langer CJ. Combined modality treatment of laryngeal squamous cell carcinoma.Expert Rev Anticancer Ther 2007 Mar;7(3):331-350.
  • Devlin JG, Langer CJ. The 800-lb gorilla we all ignore: treatment of NSCLC in elderly and PS-2 patients. Clin Adv Hematol Oncol. 2007 Mar;5(3):216-33.
  • Devlin JG, Langer CJ. Salvage therapy with vinorelbine in advanced non-small-cell lung cancer: a retrospective review of the Fox Chase Cancer Center experience and a review of the literature. Clin Lung Cancer 2007 Mar;8(5):319-26.
  • Devlin JG, Langer CJ. Salvage vinorelbine (VNR) in the 2nd to 4th line setting in advanced nonsmall cell lung cancer (NSCLC) : a retrospective review at the Fox Chase Cancer Center (FCCC). J Clin Oncol 2006 Annual ASCO Meeting Proceedings (Post-meeting edition), Vol 24, No. 18S (June 20 supplement), 2006:17072.
  • Devlin JG, Langer CJ. Ch. 28 -Adenoid Cystic Carcinoma of the Lung. In: Textbook of Uncommon Cancer 3rd edition. Raghavan D, Brecher ML, Johnson D, et al. (editors). John Wiley and Sons, 2006, pp.321-328.
  • Devlin JG, Odze RD, Cheng JD. Ch. 30 – “Uncommon Cancers of the Esophagus.” In: Textbook of Uncommon Cancer, 3rd edition. Raghavan D, Brecher ML, Johnson D, et al. (editors). John Wiley and Sons, 2006, pp.337-351.
  • Devlin JG, Rubin RN. Case in Point: Sudden One-sided Weakness in a Young Woman.Consultant 2006;46(6):617-619.
  • Devlin JG, Sherman EJ. Combined modality treatment of squamous cell cancer of the head and neck. Clin Adv Hematol Oncol 2005 May;3(5):373-381

Are you ready for our Jumpstart© with OPTIFAST® Program?

Let’s get started! Answer a few basic questions to see if Jumpstart© with OPTIFAST® Program is right for you.

We commit our TIME to you. Can you...commit to once weekly attendance in the evenings?
We commit ACCOUNTABILITY for your needs.Can you...commit to daily written tracking of nutrition and activity?
We commit ENCOURAGEMENT for your goal.Can you...commit to beginning planned physical activity?
This field is for validation purposes and should be left unchanged.